Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.
1. A composition comprising a polypeptide that comprises a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1.
2. The composition of claim 1 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.
3. The composition of claim 1 , further comprising at least one chemotherapeutic agent.
4. The composition of claim 1 , further comprising at least one immunotherapeutic agent.
5. The composition of claim 1 wherein the polypeptide is therapeutically effective.
6. A composition comprising a polypeptide that comprises a sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 1.
7. A composition comprising a fusion polypeptide comprising albumin protein linked to a FMS-like tyrosine kinase 3 ligand (Flt3L) protein, and wherein the albumin protein is murine.
8. The composition of claim 7 wherein the Flt3L protein is murine.
9. The composition of claim 7 having the amino acid sequence of SEQ ID NO: 2.
10. The composition of claim 7 having the amino acid sequence of SEQ ID NO: 3.
11. The composition of claim 7 , further comprising a pharmaceutically acceptable carrier.